With three decades of first-hand experience in conducting clinical protocols, we have gained valuable insight into the hidden challenges in biomarker quantitation that has driven our state-of-the art delivery.

This resulted in the patenting of our high sensitivity multiplex immunoassay technologies and provision of biostatistics, integrating our data production with clinical endpoints.

To address the demand for expansion in monitoring immune function we integrated targeted RNA-Seq for multiple gene expression monitoring.

Integration of Aeirtec's unique assay biochemistry technology and patented standard curve analysis equations enable Aeirtec to accurately extend sample marker measurement into the femtogram/ml region, while retaining linearity in sample dilution. This was a necessary development to capture precision data on all critical low abundance biomarkers in all samples.